Compare Novavax Inc (NVAX) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Nuscale Power Corporation — how do they compare? Novavax Inc trades at $12.64 (market cap $1.82B), while Nuscale Power Corporation trades at $7.11 (market cap $3.00B). The key difference: Nuscale Power Corporation is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Nuscale Power Corporation for 29 Days on average.
| NVAX | SMR | |
|---|---|---|
Market Cap | $1.82B | $3.00B |
Volume | 6,198,505 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $12.56 | $53.43 |
52-Week Low | $6.22 | $7.32 |
Typical Hold Time | 59 Days | 29 Days |
Enterprise Value | $1.39B | $1.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
SMR stock trades at $7.23, down 5.74% on the day, reflecting a bearish technical trend and weak financial performance. The company reported a net loss of $355.79 million in 2025 on revenue of $31.48 million, with a negative net income margin of -3,888.7%. Despite analyst consensus pointing to a $11.25 price target, recent news highlights an ongoing SEC investigation and intense competition in the small modular reactor market.
The outlook remains highly speculative, with significant execution risk and cash burn offsetting long-term potential in the nuclear energy sector. While institutional interest and a 50% buy rating suggest some optimism, the stock's high volatility and lack of profitability present substantial risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
